[323 Pages Report] The paediatric influenza treatment market is anticipated to rise to US$ 578.2 Million in 2022 and likely to reach US$ 847.7 Million by 2032 with a CAGR of 3.5% during the forecast period from 2022 to 2032.
| Report Attribute | Details |
|---|---|
| Paediatric Influenza Treatment Market Value (2022) | US$ 578.2 Million |
| Paediatric Influenza Treatment Market Anticipated Forecast Value (2032) | US$ 847.7 Million |
| Paediatric Influenza Treatment Market Projected Growth Rate (2022 to 2032) | 3.5% |
Paediatric influenza treatment market share is likely to rise due to the increasing number of patients caused by respiratory infection during the forecast period from 2022 to 2032.
The disease can spread quickly through groups as the infection is passed from individual to individual, especially in children, which is anticipated to increase in the adoption of paediatric influenza treatment in recent years.
The patient is mainly caused by influenza A or influenza B virus, which happens in outbreaks worldwide consistently, primarily during the winter seasons in calm atmospheres. These factors directly increase the demand for paediatric influenza treatment in the coming forecast period.
The paediatric influenza treatment market growth is supposed to rise by the disease; here are a few symptoms include such as high-grade fever up to 104 degrees F, chills and shakes during fever, extreme tiredness, headache and body aches, dry, hacking cough, vomiting, and belly pain are anticipated to increase the paediatric influenza treatment market size.
The paediatric influenza treatment is the critical vector for the spread of ailment. The disease may affect newborn babies widely, which leads to an attack on their lungs and can be caused death. To avoid such things, the adoption of paediatric influenza treatment is growing all over the region during the forecast period.
However, antiviral professionally prescribed medications or antiviral medications might additionally be utilized for counteractive action in high-hazard patients, which leads to boosting in the paediatric influenza treatment statistics during the forecast period from 2022 to 2032.
Children below 6 months are likely to provide flu vaccine as a treatment in the hospitals, and grow the paediatric influenza treatment market trends in the coming year.
Other treatments proposed by healthcare professionals include plenty of rest, plenty of fluids, and usage of acetaminophen or ibuprofen to lower fever and ease aches are driving the paediatric influenza treatment market share as per the paediatric influenza treatment market report.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Antiviral prescriptions are viable for the counteractive action of flu which is utilized for treatment and can diminish the span and seriousness of the disease and are likely to grow the paediatric influenza treatment market future trends in the coming year.
The development of the four authorized antiviral specialists, including oseltamivir, zanamivir, amantadine, and rimantadine, are some flowing flu infection strains that are likely to rise in the paediatric influenza treatment market analysis during the forecast period.
Expanding indications of flu between the age group of 1 to 9 years, coupled with a rise in the usage of antiviral drugs, have significantly contributed to enlarging the paediatric influenza treatment market growth.
The three influenza antiviral medicines approved by the U.S. (FDA) prescribed which are used during the flu season are oral oseltamivir (accessible as a generic drug or under the exchange name Tamiflu), zanamivir (Relenza - trade name), and intravenous peramivir (trade name Rapivab). There is raising awareness of the adoption of paediatric influenza treatment.
Late innovative headways in restorative antiviral drugs for treating different types of this sickness have additionally caused an expanded request worldwide, which will keep on contributing towards the development of paediatric influenza treatment market opportunities in the coming period.
However, there are factors such as a limited number of treatment options in developing economies coupled with the high very high cost of branded drugs, expensiveness, and inefficient usage of low-cost non-prescribed drugs, less availability of antiviral drugs with improper guidelines are the key factors that may restraint the paediatric influenza treatment market growth.
The North American region is expected to dominate the paediatric influenza treatment market share in comparison to other regions. The region acquires 34.0% of the share in the paediatric influenza treatment market size all around the region during the forecast period from 2022 to 2032.
The higher infection rate among children, higher cost of antiviral drugs and large population of patients of young age (1-9 years) suffering from paediatric influenza are leading to influence the paediatric influenza treatment market trends & forecast during the forthcoming year.
Principal Consultant
The Europe region is anticipated to grow the paediatric influenza treatment market share during the forecast period from 2022 to 2032 with a 27.3% of share in the paediatric influenza treatment market size.
High awareness levels among physicians and frequent publication of results of upcoming treatments tend to create a positive sentiment in the region, which is likely to rise the paediatric influenza treatment market demand analysis.
Healthy as well as chronically both may ill children due to the paediatric influenza virus itself or secondary bacterial infection are anticipated to grow the paediatric influenza treatment market growth.
Children should be treated and tested with neuraminidase inhibitors treatments which are more effective and tolerated against the virus and are supposed to grow the paediatric influenza treatment market future trends during the forecast period from 2022 to 2032.
Seasonal paediatric influenza treatment vaccine is more effective that helps to prevent and control the virus outbreaks.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
A few key players in the paediatric influenza treatment market are GlaxoSmithKline Plc., NATCO Pharma Limited., NESHER PHARMS, F. Hoffmann-La Roche Ltd, Atabay Kimya Sanayi ve Ticaret A.S., Cipla, Hetero Pharma, Teva Pharmaceutical Pvt. Ltd. and Olainfarm JSC.
The key player industries are emerging trends in paediatric influenza treatment market by adopting various market growth strategies including collaborations, mergers, partnerships, acquisitions, product launches and others.
Some of the recent developments in the paediatric influenza treatment market are as follows:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 3.5% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2016 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The paediatric influenza treatment market is likely to advance at a CAGR of 3.5% through 2032.
The North American region holds the paediatric influenza treatment market share of 34.0% by 2032.
The paediatric influenza treatment market is anticipated to expect US$ 578.2 Million in 2022.
The paediatric influenza treatment market is expected to account for US$ 847.7 Million by 2032.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Paediatric Influenza Treatment Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Paediatric Influenza Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Treatment Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment Type, 2022-2032 5.3.1. Adamantanes 5.3.2. Amantadine & Rimantadine 5.3.3. Neuraminidase Inhibitors 5.3.4. Oseltamivir & Zanamivir 5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Treatment Type, 2022-2032 6. Global Paediatric Influenza Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032 6.3.1. Hospitals 6.3.2. Clinics 6.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021 6.5. Absolute $ Opportunity Analysis By End User, 2022-2032 7. Global Paediatric Influenza Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021 7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Paediatric Influenza Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 8.2.1. By Country 8.2.1.1. U.S. 8.2.1.2. Canada 8.2.2. By Treatment Type 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment Type 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Paediatric Influenza Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment Type 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment Type 9.3.3. By End User 9.4. Key Takeaways 10. Europe Paediatric Influenza Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. U.K. 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Treatment Type 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment Type 10.3.3. By End User 10.4. Key Takeaways 11. Asia Pacific Paediatric Influenza Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. India 11.2.1.5. Malaysia 11.2.1.6. Singapore 11.2.1.7. Australia 11.2.1.8. New Zealand 11.2.1.9. Rest of APAC 11.2.2. By Treatment Type 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Type 11.3.3. By End User 11.4. Key Takeaways 12. MEA Paediatric Influenza Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of MEA 12.2.2. By Treatment Type 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Type 12.3.3. By End User 12.4. Key Takeaways 13. Key Countries Paediatric Influenza Treatment Market Analysis 13.1. U.S. 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2021 13.1.2.1. By Treatment Type 13.1.2.2. By End User 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2021 13.2.2.1. By Treatment Type 13.2.2.2. By End User 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2021 13.3.2.1. By Treatment Type 13.3.2.2. By End User 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2021 13.4.2.1. By Treatment Type 13.4.2.2. By End User 13.5. Germany 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2021 13.5.2.1. By Treatment Type 13.5.2.2. By End User 13.6. U.K. 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2021 13.6.2.1. By Treatment Type 13.6.2.2. By End User 13.7. France 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2021 13.7.2.1. By Treatment Type 13.7.2.2. By End User 13.8. Spain 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2021 13.8.2.1. By Treatment Type 13.8.2.2. By End User 13.9. Italy 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2021 13.9.2.1. By Treatment Type 13.9.2.2. By End User 13.10. China 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2021 13.10.2.1. By Treatment Type 13.10.2.2. By End User 13.11. Japan 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2021 13.11.2.1. By Treatment Type 13.11.2.2. By End User 13.12. South Korea 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2021 13.12.2.1. By Treatment Type 13.12.2.2. By End User 13.13. Malaysia 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2021 13.13.2.1. By Treatment Type 13.13.2.2. By End User 13.14. Singapore 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2021 13.14.2.1. By Treatment Type 13.14.2.2. By End User 13.15. Australia 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2021 13.15.2.1. By Treatment Type 13.15.2.2. By End User 13.16. New Zealand 13.16.1. Pricing Analysis 13.16.2. Market Share Analysis, 2021 13.16.2.1. By Treatment Type 13.16.2.2. By End User 13.17. GCC Countries 13.17.1. Pricing Analysis 13.17.2. Market Share Analysis, 2021 13.17.2.1. By Treatment Type 13.17.2.2. By End User 13.18. South Africa 13.18.1. Pricing Analysis 13.18.2. Market Share Analysis, 2021 13.18.2.1. By Treatment Type 13.18.2.2. By End User 13.19. Israel 13.19.1. Pricing Analysis 13.19.2. Market Share Analysis, 2021 13.19.2.1. By Treatment Type 13.19.2.2. By End User 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Treatment Type 14.3.3. By End User 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. GlaxoSmithKline Plc. 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. NATCO Pharma Limited 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. NESHER PHARMS 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. F. Hoffmann-La Roche Ltd 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Atabay Kimya Sanayi ve Ticaret A.S. 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Cipla 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. Hetero Pharma 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 15.1.8. Teva Pharmaceutical pvt. Ltd. 15.1.8.1. Overview 15.1.8.2. Product Portfolio 15.1.8.3. Profitability by Market Segments 15.1.8.4. Sales Footprint 15.1.8.5. Strategy Overview 15.1.8.5.1. Marketing Strategy 15.1.9. Olainfarm JSC 15.1.9.1. Overview 15.1.9.2. Product Portfolio 15.1.9.3. Profitability by Market Segments 15.1.9.4. Sales Footprint 15.1.9.5. Strategy Overview 15.1.9.5.1. Marketing Strategy 15.1.10. Gilead Sciences, Inc. 15.1.10.1. Overview 15.1.10.2. Product Portfolio 15.1.10.3. Profitability by Market Segments 15.1.10.4. Sales Footprint 15.1.10.5. Strategy Overview 15.1.10.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Paediatric influenza treatment market
